Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391941 | 0.89 | JAK2 (0.35) | JAK2JAK3JAK1PIK3CDMEN1 | |
| SCHEMBL24391613 | 0.87 | JAK2 (0.34) | JAK2JAK3JAK1PIK3CDMEN1 | |
| SCHEMBL24391905 | 0.87 | JAK2 (0.34) | JAK2JAK3JAK1PIK3CDMEN1 | |
| SCHEMBL24391973 | 0.85 | ENPP1 (0.34) | JAK2JAK3JAK1PIK3CDMEN1 | |
| SCHEMBL24391628 | 0.85 | JAK2 (0.36) | JAK2JAK3JAK1PIK3CD | |
| SCHEMBL24392302 | 0.85 | — | — | |
| SCHEMBL24392257 | 0.80 | PDE2A (0.39) | PIK3CDHTR2AHTR2CKIT | |
| SCHEMBL24391922 | 0.80 | JAK2 (0.36) | JAK2JAK3JAK1PIK3CDMEN1 | |
| SCHEMBL24392267 | 0.78 | IRAK4 (0.44) | JAK2JAK3JAK1PIK3CDHTR2A | |
| SCHEMBL24391934 | 0.77 | PIK3CD (0.40) | JAK2JAK3JAK1PIK3CDCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | JAK2 3057/4885JAK3 4026/4885JAK1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.